We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$589M
AUM Growth
+$77.1M
Cap. Flow
+$17.1M
Cap. Flow %
2.91%
Top 10 Hldgs %
37.04%
Holding
153
New
41
Increased
30
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.2M
2
GILD icon
Gilead Sciences
GILD
+$15.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
TSRO
TESARO, Inc.
TSRO
+$7.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.09M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.32M
4
NVS icon
Novartis
NVS
+$4.35M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 66.11%
2 Technology 6.31%
3 Industrials 2.63%
4 Communication Services 2.28%
5 Financials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVOK
101
DELISTED
Evoke Pharma
EVOK
$1.28M 0.22%
3,472
– –
KRNT icon
102
Kornit Digital
KRNT
$705M
$1.11M 0.19%
57,300
+56,400
+6,267% +$1.09M
XLRN
103
DELISTED
Acceleron Pharma
XLRN
$1.06M 0.18%
35,000
-65,000
-65% -$1.88M
VTGN icon
104
VistaGen Therapeutics
VTGN
$9.89M
$1.02M 0.17%
18,137
– –
NGNE icon
105
Neurogene
NGNE
$656M
$874K 0.15%
+3,104
New +$888K
VRSK icon
106
Verisk Analytics
VRSK
$25.4B
$793K 0.13%
+9,400
New +$761K
RCKT icon
107
Rocket Pharmaceuticals
RCKT
$340M
$763K 0.13%
100,441
– –
XENE icon
108
Xenon Pharmaceuticals
XENE
$6.06B
$718K 0.12%
228,029
-100,000
-30% -$391K
VIRX
109
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$522K 0.09%
5,520
+1,949
+55% +$224K
CAMT icon
110
Camtek
CAMT
$6.18B
$478K 0.08%
+99,035
New +$481K
ATXS
111
DELISTED
Astria Therapeutics
ATXS
$409K 0.07%
4,801
-1,666
-26% -$139K
SAGE
112
DELISTED
Sage Therapeutics
SAGE
$398K 0.07%
5,000
-45,000
-90% -$3.25M
UNH icon
113
UnitedHealth
UNH
$376B
$371K 0.06%
2,000
– –
WSO icon
114
Watsco Inc
WSO
$12.7B
$324K 0.06%
+2,100
New +$300K
NVMI
115
Nova
NVMI
$12.4B
$306K 0.05%
+13,844
New +$308K
MHK icon
116
Mohawk Industries
MHK
$7.5B
$266K 0.05%
1,100
– –
PTN
117
Palatin Technologies
PTN
$13.7M
$203K 0.03%
377
-1,948
-84% -$933K
LOW icon
118
Lowe's Companies
LOW
$117B
$202K 0.03%
2,600
– –
SEE
119
DELISTED
Sealed Air
SEE
$201K 0.03%
4,500
– –
TMX
120
DELISTED
Terminix Global Holdings, Inc.
TMX
$196K 0.03%
7,465
– –
ULTI
121
DELISTED
Ultimate Software Group Inc
ULTI
$168K 0.03%
800
– –
CMG icon
122
Chipotle Mexican Grill
CMG
$47.2B
$166K 0.03%
20,000
– –
XRAY icon
123
Dentsply Sirona
XRAY
$2.68B
$162K 0.03%
+2,500
New +$158K
LVNTA
124
DELISTED
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
$157K 0.03%
+3,000
New +$157K
TRIP icon
125
TripAdvisor
TRIP
$1.65B
$153K 0.03%
4,000
– –
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sphera Funds Management held 153 positions worth $589M, up 15% from $512M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management's Q2 2017 filing shows 41 new, 30 increased, 20 reduced and 25 closed positions. Its largest new stake was GSK: 360,000 shares worth $19.4M. The largest sale was Shire pic, an estimated $25.5M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q2 2017 buy was GSK: 360,000 shares worth $19.4M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $5.33M increase.
  • Sphera Funds Management's biggest Q2 2017 reduction was Shire pic, cutting an estimated $25.5M.
  • Sphera Funds Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $7.09M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $589M portfolio in Q2 2017.
  • Sphera Funds Management opened 41 new positions and closed 25 in Q2 2017.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $589M.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.